Bone Health Updates: “Breaking” Down Literature in Special Populations for Treatments of Osteoporosis and Other Bone Disorders

NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board-certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

Despite the devastating effects that osteoporosis can have on a patient’s quality of life, most of the data used to inform the treatment of osteoporosis has been extrapolated from studies of postmenopausal women and does not include special populations, who have a significant risk of osteoporosis-related morbidity and mortality. This session will focus on updated guidelines on osteoporosis treatment and discuss their use in specific patient populations, including men, patients with steroid-induced osteoporosis, geriatric patients, and children. Updates regarding the removal of the boxed warning for parathyroid hormone (PTH) analogs, as well as the post-marketing surveillance literature that led to the warning’s removal, are discussed, as are suggestions for moving forward with the use of PTH analogs in osteoporosis treatment.

This activity is approved for Board-Certified Ambulatory Care Pharmacist (BCACP) and Board-Certified Geriatric Pharmacist (BCGP) recertification credit.